An estimated two billion people lack the medicines they need. The 2016 Access to Medicines Index analyzes pharmaceutical companies’ efforts to improve access to medicines, vaccines and diagnostics for low- and middle-income countries.

Sabin Vaccine Institute President Dr. Peter Hotez gave the keynote address on NTDs at the Pontifical Council for Health Care Workers’ XXXI International Conference, focused on NTDs and rare diseases.

By the Dengue Vaccine Initiative

Dr. Sazaly has been involved with dengue research for over 20 years and has also maintained strong research interest in emerging infectious diseases. His interest in dengue, in particular, is rooted in its knowledge gaps: “it is a fascinating disease needing a lot more research to take on.” In an interview with DVI, Dr. Sazaly shares more on his views of dengue prevention and control and needs in the dengue research field.

This blog was originally published by the Dengue Vaccine Initiative.

Every three months, the Dengue Vaccine Initiative (DVI) highlights a “Dengue Champion,” calling attention to that person’s contribution to the dengue vaccine research field and their commitment to the fight against dengue fever. Dr.

Dr. Capeding led the first Phase 3 trial ever completed for a dengue vaccine candidate.

Titled, “New chapter unfolding in the fight against dengue with an unwritten ending,” the Dengue Vaccine Initiative’s (DVI) editorial just published in the October issue of Transactions

Pages